An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
NCT03882918
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
141
Enrollment
INDUSTRY
Sponsor class
Stopped
Company decision
Conditions
Angelman Syndrome
Interventions
DRUG:
OV101
Sponsor
Healx AI